We are live on ! Find out more
AA

AlphaCentric Advisors Portfolio holdings

AUM $100M
This Fund
S&P 500
This Quarter Est. Return
+4.14%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$100M
AUM Growth
-$34.3M
Cap. Flow
-$33.3M
Cap. Flow %
-33.2%
Top 10 Hldgs %
26.12%
Holding
294
New
64
Increased
32
Reduced
107
Closed
85

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$5.08M
2
UNH icon
UnitedHealth
UNH
+$4.05M
3
JNJ icon
Johnson & Johnson
JNJ
+$2.82M
4
NVO
Novo Nordisk
NVO
+$2.52M
5
ABBV icon
AbbVie
ABBV
+$2.39M

Top Sells

Rank Stock Value
1
RITM icon
Rithm Capital
RITM
+$4.32M
2
HRMY icon
Harmony Biosciences
HRMY
+$3.88M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$3.12M
4
EFC
Ellington Financial
EFC
+$2.6M
5
MTG icon
MGIC Investment
MTG
+$2.54M

Sector Composition

Rank Sector Weight
1 Healthcare 54.58%
2 Real Estate 7.4%
3 Industrials 5.96%
4 Financials 5.87%
5 Technology 4.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GPK icon
26
Graphic Packaging
GPK
$3.2B
$1.09M 1.08%
+40,000
New +$1.16M
ABT icon
27
Abbott
ABT
$175B
$1.06M 1.05%
+9,333
New +$1.08M
PFE icon
28
Pfizer
PFE
$143B
$1.03M 1.03%
38,807
+3,807
+11% +$103K
ELV icon
29
Elevance Health
ELV
$80.9B
$997K 0.99%
+2,702
New +$1.13M
GILD icon
30
Gilead Sciences
GILD
$167B
$976K 0.97%
10,562
+7,062
+202% +$636K
DHR icon
31
Danaher
DHR
$144B
$958K 0.96%
+4,175
New +$1.03M
GNW icon
32
Genworth Financial
GNW
$3.86B
$937K 0.93%
+134,000
New +$962K
BDX icon
33
Becton Dickinson
BDX
$43.6B
$892K 0.89%
+3,930
New +$907K
ATRC icon
34
AtriCure
ATRC
$1.77B
$796K 0.79%
+26,035
New +$837K
CTO
35
CTO Realty Growth
CTO
$751M
$788K 0.79%
+40,000
New +$787K
VRNA
36
DELISTED
Verona Pharma
VRNA
$753K 0.75%
16,211
-33,789
-68% -$1.27M
AXR icon
37
AMREP Corp
AXR
$136M
$719K 0.72%
+22,899
New +$739K
ROK icon
38
Rockwell Automation
ROK
$51.4B
$714K 0.71%
2,500
+250
+11% +$70.3K
CIM
39
Chimera Investment
CIM
$1.08B
$700K 0.7%
50,000
+35,978
+257% +$539K
ARAY icon
40
Accuray
ARAY
$30.8M
$693K 0.69%
350,000
– –
EW icon
41
Edwards Lifesciences
EW
$49.4B
$691K 0.69%
+9,333
New +$653K
EXAS
42
DELISTED
Exact Sciences
EXAS
$662K 0.66%
11,790
-18,210
-61% -$1.13M
PRCT icon
43
Procept Biorobotics
PRCT
$1.09B
$644K 0.64%
8,000
– –
RKLB icon
44
Rocket Lab Corp
RKLB
$42.3B
$637K 0.64%
25,000
+10,000
+67% +$176K
EHC icon
45
Encompass Health
EHC
$11.1B
$635K 0.63%
+6,877
New +$675K
ZBH icon
46
Zimmer Biomet
ZBH
$17.6B
$623K 0.62%
+5,895
New +$633K
SYK icon
47
Stryker
SYK
$123B
$619K 0.62%
+1,719
New +$637K
NVDA icon
48
NVIDIA
NVDA
$4.91T
$582K 0.58%
4,335
-1,646
-28% -$227K
SMRT icon
49
SmartRent
SMRT
$186M
$569K 0.57%
+325,000
New +$544K
HOLX
50
DELISTED
Hologic
HOLX
$549K 0.55%
+7,614
New +$595K
1
2
3 4 5

Similar funds

WCM
Weber Capital Management San Francisco, California $100M AUM
FCM
Fourier Capital Management Hong Kong $100M AUM
BIA
Baer Investment Advisory Corte Madera, California $100M AUM 23.87% 1-Year Est. Return
AGAM
Audent Global Asset Management West Hollywood, California $100M AUM 22.83% 1-Year Est. Return
E
Entelevest Coral Gables, Florida $100M AUM
HCM
Hicks Capital Management Columbus, Ohio $100M AUM 14.29% 1-Year Est. Return
AC
Arrow Capital Sydney, Australia $100M AUM 68.52% 1-Year Est. Return
OIS
OneAscent Investment Solutions Birmingham, Alabama $100M AUM 15.97% 1-Year Est. Return

AlphaCentric Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, AlphaCentric Advisors held 294 positions worth $100M, down 25% from $135M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

AlphaCentric Advisors withdrew a net $33.3M in Q4 2024, closing 85 positions and reducing 107 holdings. Its most notable exit was Rithm Capital, an estimated $4.32M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 58% a quarter earlier, followed by Real Estate and Industrials.

Against the trend, AlphaCentric Advisors opened a new position in Eli Lilly worth $4.74M.

  • AlphaCentric Advisors's largest Q4 2024 buy was Eli Lilly: 6,140 shares worth $4.74M.
  • AlphaCentric Advisors added most to iShares 1-3 Year Treasury Bond ETF in Q4 2024, an estimated $2.03M increase.
  • AlphaCentric Advisors's biggest Q4 2024 reduction was Neurocrine Biosciences, cutting an estimated $2.33M.
  • AlphaCentric Advisors fully exited Rithm Capital in Q4 2024, selling an estimated $4.32M.
  • AlphaCentric Advisors's ten largest holdings make up 26% of its $100M portfolio in Q4 2024.
  • AlphaCentric Advisors opened 64 new positions and closed 85 in Q4 2024.
  • AlphaCentric Advisors's portfolio value fell 25% quarter-over-quarter to $100M.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.